Camurus AB (publ) (CAMX.ST)
- Previous Close
543.50 - Open
549.00 - Bid 539.50 x --
- Ask 540.50 x --
- Day's Range
532.50 - 550.50 - 52 Week Range
483.80 - 715.00 - Volume
108,957 - Avg. Volume
88,181 - Market Cap (intraday)
31.795B - Beta (5Y Monthly) --
- PE Ratio (TTM)
75.31 - EPS (TTM)
7.17 - Earnings Date Jul 17, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
737.29
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029, which completed phase III clinical trials for the treatment of acromegaly, and phase III clinical trials to treat gastroenteropancreatic neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM2056 that is in phase I clinical trials for the treatment of metabolic diseases; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; and Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity, as well as NewBridge Pharmaceuticals. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.
www.camurus.comRecent News: CAMX.ST
View More
Performance Overview: CAMX.ST
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CAMX.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CAMX.ST
View MoreValuation Measures
Market Cap
32.00B
Enterprise Value
29.17B
Trailing P/E
75.49
Forward P/E
38.17
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
17.32
Price/Book (mrq)
9.73
Enterprise Value/Revenue
15.62
Enterprise Value/EBITDA
51.33
Financial Highlights
Profitability and Income Statement
Profit Margin
26.91%
Return on Assets (ttm)
11.09%
Return on Equity (ttm)
17.86%
Revenue (ttm)
2.04B
Net Income Avi to Common (ttm)
547.78M
Diluted EPS (ttm)
7.17
Balance Sheet and Cash Flow
Total Cash (mrq)
2.88B
Total Debt/Equity (mrq)
3.06%
Levered Free Cash Flow (ttm)
145.92M